Keflavo

Micronised Purified Flavonoic Fraction, the active ingredient in Keflavo, is an oral pharmaceutical presented as a micronised purified flavonoic fraction for oral use. It is investigated for potential therapeutic roles in flavonoid‑related pathways, though specific approved indications are not established.

GNH USA supplies Keflavo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Keflavo contains Micronised Purified Flavonoic Fraction, a flavonoid‑derived compound studied in vascular and oxidative‑stress pathways.

- No approved indications: The ingredient is not currently assigned a specific therapeutic use.

Adverse reactions reported for Keflavo are limited due to its investigational status.

Common Side Effects: - None reported in clinical studies. - Mild gastrointestinal discomfort: occasional transient nausea. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Allergic reaction: rare hypersensitivity with rash or pruritus. - Anaphylaxis: extremely rare, requires immediate medical attention. - Hepatic enzyme elevation: rare, monitor liver function if used long term. - Severe gastrointestinal bleeding: very rare, especially if combined with anticoagulants.

When considering Keflavo, several safety considerations should be observed. - Pregnancy: safety not established; avoid use unless clearly needed. - Breastfeeding: unknown excretion; weigh potential risks and benefits. - Renal impairment: use with caution; dose adjustment may be required. - Hepatic disease: monitor liver function tests during prolonged use. - Drug interactions: no well‑documented interactions, but monitor concomitant therapies. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Keflavo may interact with other medicines, although data are limited.

Major Interactions (Avoid): - None identified: no documented major drug‑drug interactions.

Moderate Interactions (Monitor Closely): - Anticoagulants: potential additive effect on bleeding risk; monitor coagulation parameters. - CYP450 substrates: flavonoids can modulate enzyme activity; observe for altered plasma levels of sensitive drugs. - Iron supplements: may reduce flavonoid absorption; separate administration by at least two hours.